LiverPro and the new Lancet prospective cohort study
Автор: Michael Betel, President, Fatty Liver Alliance
Загружено: 2025-02-20
Просмотров: 109
In a recent video chat, Michael Betel, President and Founder of the Fatty Liver Alliance, interviewed Taus Holtug, CEO and Co-Founder, and Dr. Katrine Prier Lindvig, CMO and Co-Founder of Evido Health, following the publication of their innovative study in The Lancet Gastroenterology and Hepatology (DOI: 10.1016/S2468-1253(24)00274-7). Recognizing the significance of their research, the Fatty Liver Alliance wanted to learn more about LiverPro, Evido Health’s software-based tool that empowers healthcare professionals to identify liver disease earlier in a patient's journey.
Study: "Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study"
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
